TrialThe Journal of dermatology2022

Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: Final analysis of a 52-week phase 3 open-label study.

Kenshi Yamasaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.